CD40 and myeloid sarcoma: Our data reveal that blocking CD40 in a cell type‐specific manner, or inhibition of parts of the CD40 signaling, has great therapeutic potential for the treatment of MS, as it will cause limited immune‐suppressive side‐effects compared with untargeted inhibition of the entire CD40 pathway.